The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling

[1]  Dasatinib , 2019, Reactions Weekly.

[2]  M. Absalon,et al.  A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) , 2017, Pediatric blood & cancer.

[3]  M. Konopleva,et al.  A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia , 2017, Blood Cancer Journal.

[4]  E. Heath,et al.  Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis , 2016, Molecular Cancer.

[5]  U. Dirksen,et al.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease , 2016, Molecular oncology.

[6]  B. Snaar-Jagalska,et al.  CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. , 2015, European journal of cancer.

[7]  A. Jochemsen,et al.  Novel splice variants of CXCR4 identified by transcriptome sequencing. , 2015, Biochemical and biophysical research communications.

[8]  U. Dirksen,et al.  3406 Receptor tyrosine kinase gene expression analyses of Ewing sarcomas identify ROR1 as a potential therapeutic target in metastatic disease , 2015 .

[9]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Triche,et al.  Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour–stromal interactions: a report from the Children's Oncology Group , 2015, The journal of pathology. Clinical research.

[11]  U. Dirksen,et al.  Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. , 2014, Oncology reports.

[12]  Dafydd G. Thomas,et al.  Stress-Induced CXCR4 Promotes Migration and Invasion of Ewing Sarcoma , 2014, Molecular Cancer Research.

[13]  J. Galzi,et al.  Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer , 2014, Molecular Cancer.

[14]  E. Kleinerman,et al.  Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors , 2013, Molecular Cancer Therapeutics.

[15]  U. Dirksen,et al.  The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease , 2012, Clinical Sarcoma Research.

[16]  Zhe Jin,et al.  Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression , 2012, BMC Cancer.

[17]  G. Vassal,et al.  Involvement of the CXCR7/CXCR4/CXCL12 Axis in the Malignant Progression of Human Neuroblastoma , 2012, PloS one.

[18]  C. Locht,et al.  The ins and outs of pertussis toxin , 2011, The FEBS journal.

[19]  E. Kleinerman,et al.  SDF-1α Induces PDGF-B Expression and the Differentiation of Bone Marrow Cells into Pericytes , 2011, Molecular Cancer Research.

[20]  P. Ghadjar,et al.  CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells , 2011, Journal of Translational Medicine.

[21]  M. Ratajczak,et al.  Overlapping and distinct role of CXCR7‐SDF‐1/ITAC and CXCR4‐SDF‐1 axes in regulating metastatic behavior of human rhabdomyosarcomas , 2010, International journal of cancer.

[22]  Ji-Young Hwang,et al.  The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  U. Dirksen,et al.  Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Aaron R Cooper,et al.  Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma , 2010, Clinical Cancer Research.

[25]  M. Ratajczak,et al.  The role of stromal-derived factor-1--CXCR7 axis in development and cancer. , 2009, European journal of pharmacology.

[26]  J. Maris,et al.  CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation , 2009, Molecular Cancer.

[27]  N. Heveker,et al.  AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties , 2009, Molecular Pharmacology.

[28]  D. Wong,et al.  Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.

[29]  S. Keir,et al.  Initial testing of dasatinib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[30]  M. Pierotti,et al.  Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors , 2007 .

[31]  R. Jove,et al.  Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. , 2007, Cancer research.

[32]  E. Estey,et al.  Overexpression of CXCR4 predicts adverse overall and event‐free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype , 2007, Cancer.

[33]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[34]  R. Wong,et al.  Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. , 2006, Biochemical pharmacology.

[35]  S. McColl,et al.  Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. , 2006, Cancer research.

[36]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[37]  A. Amadori,et al.  CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications , 2006, Clinical Cancer Research.

[38]  A. Sahin,et al.  CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. , 2005, Cancer research.

[39]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[40]  Hiroya Takeuchi,et al.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Broder,et al.  Marked structural and functional heterogeneity in CXCR4: Separation of HIV‐1 and SDF‐1α responses , 2005, Immunology and cell biology.

[42]  P. Allavena,et al.  Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4 , 2004, Cancer Research.

[43]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[44]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[45]  M. Burdick,et al.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.

[46]  M. Ladanyi,et al.  Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells , 2003, Oncogene.

[47]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[48]  E. De Clercq,et al.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 , 2002, FEBS letters.

[49]  J. Broach,et al.  A Point Mutation That Confers Constitutive Activity to CXCR4 Reveals That T140 Is an Inverse Agonist and That AMD3100 and ALX40-4C Are Weak Partial Agonists* , 2002, The Journal of Biological Chemistry.

[50]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[51]  K. Pillarisetti,et al.  Modulation of CXCR4 expression and SDF‐1α functional activity during differentiation of human monocytes and macrophages , 1999, Journal of leukocyte biology.

[52]  E. D. de Vries,et al.  A review on CXCR4/CXCL12 axis in oncology: no place to hide. , 2013, European journal of cancer.

[53]  G. Calandra,et al.  Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[54]  M. Pierotti,et al.  Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. , 2007, Cancer.

[55]  J. Stewart.  No place to hide , 1996, Nature.